Top

Journal of Mammary Gland Biology and Neoplasia

Published in:

01-12-2009

Ex-vivo Analysis of the Bone Microenvironment in Bone Metastatic Breast Cancer

Authors: Karen M. Bussard, Andrea M. Mastro

Published in: Journal of Mammary Gland Biology and Neoplasia | Issue 4/2009

Abstract

In humans, breast cancer has a predilection to metastasize to the skeleton. While the mechanism for preferential metastasis is unknown, the bone microenvironment likely provides a fertile soil for metastatic breast cancer cells. In order to examine the bone microenvironment ex-vivo following the formation of breast cancer metastases, several techniques may be employed: fluorescence stereomicroscopy, magnetic resonance imaging (MRI), microCT (μCT), immunohistochemistry, and cytokine arrays, to name a few. These methods allow for a comprehensive evaluation of the bone microenvironment during bone metastatic breast cancer. By identifying alterations in the bone niche caused by metastatic breast cancer cells, it may be possible to block or disrupt these factors through the use of targeted drugs. Appropriate therapeutic treatment would allow for an improved quality of life and longer survival time for individuals with bone metastatic breast cancer.

Society AC. Cancer facts and figures 2009. Atlanta: American Cancer Society; 2009.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin. 2009;59:225–49.CrossRefPubMed

Rubens RD, Mundy GR. Cancer and the skeleton. London: Martin Dunitz; 2000.

Galasko CS. Mechanisms of lytic and blastic metastatic disease of bone. Clin Orthop. 1982;169:20–7.PubMed

Guise TA, Mundy GR. Cancer and bone. Endocr Rev. 1998;19:18–54.CrossRefPubMed

Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584–93.CrossRefPubMed

Martin TJ, Moseley JM. Mechanisms in the skeletal complications of breast cancer. Endocr Rel Cancer. 2000;7:271–84.CrossRef

Chirgwin JM, Guise TA. Cancer metastasis to bone. Sci Med. 2003;9:140–51.

Cailleau R, Olive M, Cruciger QV. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro. 1978;14:911–5.CrossRefPubMed

10.

Yoneda T, Sasaki A, Mundy GR. Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat. 1994;32:73–84.CrossRefPubMed

11.

Price JE. Metastasis from human breast cancer cell lines. Breast Cancer Res Treat. 1996;39:93–102.CrossRefPubMed

12.

Phadke PA, Vaidya KS, Nash KT, Hurst DR, Welch DR. BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process. Am J Pathol. 2008;172:809–17.CrossRefPubMed

13.

Soule H, McGrath CM. Inventors; Immortal human mammary epithelial cell lines. United States patent 5,026,637. 1991.

14.

Siciliano MJ, Barker PE, Cailleau R. Mutually exclusive genetic signatures of human breast tumor cell lines with a common chromosomal marker. Cancer Res. 1979;39:919–22.PubMed

15.

Cailleau R, Young R, Olive M, Reeves WJ Jr. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst. 1974;53:661–74.PubMed

16.

Yoneda T. Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci. 2000;5:75–81.CrossRefPubMed

17.

Peyruchaud O, Winding B, Pecheur I, Serre C-M, Delmas P, Clezardin P. Early detection of bone metastases in a murine model using fluorescent human breast cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res. 2001;16:2027–34.CrossRefPubMed

18.

Kalikin LM, Schneider A, Thakur MA, et al. In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biol Ther. 2003;2:656–60.PubMed

19.

Sun Y-X, Schneider A, Jung Y, et al. Skeletal localization and neutralization of the SDF-1 (CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Min Res. 2004;20:318–29.CrossRef

20.

Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Res. 2003;3:537–49.

21.

Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R. A bone-seeking clone exhibits different biological properties from the MDA-MD-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res. 2001;16:1486–95.CrossRefPubMed

22.

Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol. 2007;170:793–804.CrossRefPubMed

23.

Phadke PA, Mercer RR, Harms JF, et al. Kinetics of metastatic breast cancer cell trafficking in bone. Clin Cancer Res. 2006;12:1431–40.CrossRefPubMed

24.

DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adapative and innate immune cells during breast cancer progression. Breast Cancer Res. 2007;9:212.CrossRefPubMed

25.

DeNardo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 2008;27:11–8.CrossRefPubMed

26.

Wick M, Dubey P, Koeppen H, et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion of systemic anergy. J Exp Med. 1997;186:229–38.CrossRefPubMed

27.

Slettenaar VIF, Wilson JL. The chemokine network: a target in cancer biology? Adv Drug Deliv Rev. 2006;58:962–74.CrossRefPubMed

28.

Fitzgerald KA, O’Neill LAJ, Gearing AJH, Callard RE. The cytokine facts book. 2nd ed. San Diego: Academic; 2001.

29.

de Zoeten EF, Carr-Brendel V, Cohen EP. Resistance to melanoma in mice immunized with semiallogeneic fibroblasts transfeced with DNA from mouse melanona cells. J Immunol. 1998;160:2915–22.PubMed

30.

Braun S, Thioudellet C, Rodriguez P, et al. Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice. Gene Ther. 2000;7:1447–57.CrossRefPubMed

31.

Kuperwasser C, Dessain S, Bierbaum BE, et al. A mouse model of human breast cancer metastasis to human bone. Cancer Res. 2005;65:6130–8.CrossRefPubMed

32.

Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52:1399–405.PubMed

33.

Lelekakis M, Moseley JM, Martin TJ, et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 1999;17:163–70.CrossRefPubMed

34.

Gupta PB, Kuperwasser C. Disease models of breast cancer. Drug Discov Today. 2004;1:9–16.

35.

Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protoncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Aca Sci USA. 1992;89:10578–82.CrossRef

36.

Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor β signaling impairs neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Aca Sci USA. 2003;100:8430–5.CrossRef

37.

Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer. 2000;88:2892–8.CrossRefPubMed

38.

Bendre M, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone. 2003;33:28–37.CrossRefPubMed

39.

Bendre M, Gaddy D, Nicholas RW, Suva LJ. Breast cancer metastasis to bone. Clin Orthop Relat Res. 2003;415S:S39–45.CrossRef

40.

Bendre M, Gaddy-Kurten D, Foote-Mon T, et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res. 2002;62:5571–9.PubMed

41.

Mastro AM, Gay CV, Welch DR, et al. Breast cancer cells induce osteoblast apoptosis: a possible contributor to bone degradation. J Cell Biochem. 2004;91:265–76.CrossRefPubMed

42.

Mercer R, Miyasaka C, Mastro AM. Metastatic breast cancer cells suppress osteoblast adhesion and differentiation. Clin Exp Metastasis. 2004;21:427–35.CrossRefPubMed

43.

Mercer R, Mastro AM. Cytokines secreted by bone-metastatic breast cancer cells alter the expression pattern of f-actin and reduce focal adhesion plaques in osteoblasts through PI3K. Exp Cell Res. 2005;310:270–81.CrossRefPubMed

44.

Kinder M, Chislock EM, Bussard KM, Shuman LA, Mastro AM. Metastatic breast cancer induces an osteoblast inflammatory response. Exp Cell Res. 2008;314:173–83.CrossRefPubMed

45.

Harms JF, Budgeon LR, Christensen ND, Welch DR. Maintaining GFP tissue fluorescence through bone decalcification and long-term storage. BioTechniques. 2002;33:1197–200.PubMed

Title: Ex-vivo Analysis of the Bone Microenvironment in Bone Metastatic Breast Cancer
Authors: Karen M. Bussard
Andrea M. Mastro
Publication date: 01-12-2009
Publisher: Springer US
Published in: Journal of Mammary Gland Biology and Neoplasia / Issue 4/2009
Print ISSN: 1083-3021
Electronic ISSN: 1573-7039
DOI: https://doi.org/10.1007/s10911-009-9159-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2009

Adipose-Depleted Mammary Epithelial Cells and Organoids

In Memoriam: H. Allen Tucker (1936–2009)

Hormone-Responsive Model of Primary Human Breast Epithelium

Lentivirus Vectors for Stably Introducing Genes into Mammary Epithelial Cells in Vivo

Methods for Collecting Milk from Mice

Methods in Mammary Gland Biology and Breast Cancer Research: An Update

Keynote webinar | Spotlight on antibody–drug conjugates in cancer